Kosaka Kinshi, Yashiro Masakazu, Sakate Yoji, Hirakawa Kosei
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Dig Dis Sci. 2007 Aug;52(8):1946-53. doi: 10.1007/s10620-006-9637-8. Epub 2007 Apr 3.
The co-stimulatory molecule CD80 is a ligand of CD28, which plays a key role in the induction of cell-mediated immune responses. Many tumors, including gastric cancer, decrease the expression of CD80, which results in the failure of immune recognition. We evaluated the effect of interleukin-2 addition combined with CD80 infection on the peritoneal metastasis in gastric cancer. CD80 infection combined with interleukin-2 addition significantly increased the activated cytotoxicity of mononuclear cells compared to CD80 gene infection and compared to the lacZ control group. In vivo, the survival of animals with intraperitoneal tumor was longest in those given CD80 infection with interleukin-2 addition (median survival, 46 days), followed by those given interleukin-2 (39 days), those given CD80 infection (37 days), and those given lacZ (29 days). These results suggest that interleukin-2 addition might contribute to improving the observed outcome of CD80 immunogene therapy in peritoneal metastasis of gastric carcinoma.
共刺激分子CD80是CD28的配体，在诱导细胞介导的免疫反应中起关键作用。包括胃癌在内的许多肿瘤会降低CD80的表达，从而导致免疫识别失败。我们评估了添加白细胞介素-2联合CD80感染对胃癌腹膜转移的影响。与CD80基因感染相比以及与lacZ对照组相比，添加白细胞介素-2联合CD80感染显著增加了单核细胞的活化细胞毒性。在体内，腹腔内有肿瘤的动物中，接受CD80感染并添加白细胞介素-2的动物存活时间最长（中位生存期为46天），其次是接受白细胞介素-2的动物（39天）、接受CD80感染的动物（37天）和接受lacZ的动物（29天）。这些结果表明，添加白细胞介素-2可能有助于改善CD80免疫基因疗法在胃癌腹膜转移中的观察结果。
